News & Events

Monthly Weekly Daily List Grid Tile
No event found!

News

PAS, An Interview with Lynda Sutton

Press Releases

Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model

The incidence of pancreatic cancer is increasing significantly and will soon become the second leading cause of cancer-related deaths in the United States. We have previously
shown that the gastrointestinal peptide gastrin, which is only expressed in the fetal pancreas and not in the adult pancreas, is activated during pancreatic carcinogenesis
where it stimulates growth in an autocrine fashion. In this investigation, we used transgenic LSL-KrasG12D/þ; P48-Cre mice that develop precancerous pancreatic intraepithelial neoplasia (PanIN) lesions and pancreatic cancer over time. Starting at 3 months of age, mice were either left untreated (control) or were treated with a gastrin-targeted vaccine,
polyclonal antibody stimulator (PAS 250 mg) followed by a monthly booster until the mice reached 8 months of age when pancreata were excised, and analyzed by histology for PanIN grade in a blinded fashion. Highgrade PanIN-3 lesions were significantly less in PAStreated mice (P ¼ 0.0077), and cancers developed in 33% of the control mice but only in 10% of the PAStreated
mice. Compared with the control mice, fibrosis was reduced by >50%, arginase positive M2 macrophages were reduced by 74%, and CD8þ T cells were increased
by 73% in the pancreas extracellular matrix in PAS-treated mice.

March 18, 2021 – Cancer Advances, Inc. Announces Abstract at AACR

Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces that an abstract will be included in the upcoming 2021 American Association of Cancer Research (AACR) Annual Meeting being held virtually...

November 11, 2019 – Cancer Advances, Inc. announces a new publication “Vaccine Against Gastrin, a Polyclonal Antibody Stimulator, Decreases Pancreatic Cancer Metastases” in the American Journal of Physiology—Gastrointestinal and Liver Physiology

• Immune competent female mice with pancreatic cancer treated with Polyclonal Antibody Stimulator (PAS) vaccine had significantly smaller tumors and fewer metastases than control mice. • PAS vaccine decreased metastasis by decreasing key pathway proteins involved in...

November 11, 2019 – Cancer Advances, Inc. announces new publication: “Gastrin Vaccine Improves Response to Immune Checkpoint Antibody in Murine Pancreatic Cancer by Altering the Tumor Microenvironment”, in the journal Cancer Immunology, Immunotherapy

• Inactivation of the growth peptide gastrin modulates the tumor microenvironment of pancreatic cancer rendering it more susceptible to immune checkpoint antibody therapy. • Polyclonal Antibody Stimulator (PAS) monotherapy elicits both a humoral and a cellular immune...

Pioneering new medicines and redefining possibilities for cancer patients.

Cancer Advances
Westpark Corporate Center
4364 South Alston Avenue,
Suite 105 Durham, North Carolina
USA 27713

© 2020 Cancer Advances, Inc. All rights reserved.